{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:26:56Z","timestamp":1775248016179,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007148","name":"Bundesministerium f\u00fcr Wissenschaft und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.yebeh.2020.107035","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T16:12:46Z","timestamp":1584979966000},"page":"107035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Second-line treatments in benzodiazepine-resistant convulsive status epilepticus: An updated network meta-analysis including the ESET Trial \u2013 What did change?"],"prefix":"10.1016","volume":"106","author":[{"given":"Francesco","family":"Brigo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107035_bb0005","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2014report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"Pt B","key":"10.1016\/j.yebeh.2020.107035_bb0010","article-title":"Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis","volume":"101","author":"Brigo","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107035_bb0015","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40263-016-0388-6","article-title":"Phenobarbital versus valproate for generalized convulsive status epilepticus in adults: a prospective randomized controlled trial in China","volume":"30","author":"Su","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2020.107035_bb0020","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2020.107035_bb0025","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1468-1331.2011.03420.x","article-title":"Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study","volume":"18","author":"Chen","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2020.107035_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2020.107035_bb0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","article-title":"Perampanel in the treatment of status epilepticus: a systematic review of the literature","volume":"86","author":"Brigo","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107035_bb0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40263-019-00652-0","article-title":"Intravenous brivaracetam in the treatment of status epilepticus: a systematic review","volume":"33","author":"Brigo","year":"2019","journal-title":"CNS Drugs"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020302146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020302146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:34:15Z","timestamp":1761503655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020302146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":8,"alternative-id":["S1525505020302146"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107035","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line treatments in benzodiazepine-resistant convulsive status epilepticus: An updated network meta-analysis including the ESET Trial \u2013 What did change?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107035"}}